Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

202.86 -2.84 (-1.38%)
Streaming Delayed Price Updated: 10:24 AM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
News headline image
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: Moderna (NASDAQ:MRNA)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna... 
Via StockStory
Topics Artificial Intelligence
UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression ↗
Via Stocktwits
News headline image
1 S&P 500 Stock on Our Watchlist and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Analyst Expectations For Biogen's Future ↗
 
Via Benzinga
News headline image
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
News headline image
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot ↗
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon. 
Via Benzinga
Topics Stocks
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Biogen's Earnings Outlook ↗
 
Via Benzinga
News headline image
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Biogen Inc.
Via GlobeNewswire
News headline image
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
From Biogen Inc.
Via GlobeNewswire
News headline image
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs ↗
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
News headline image
2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Wondering what's happening in today's S&P500 pre-market session? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
News headline image
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly. 
Via Benzinga
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above... 
Via StockStory
News headline image
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
Beyond The Numbers: 8 Analysts Discuss Biogen Stock ↗
 
Via Benzinga
News headline image
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate ↗
Biogen beat Q2 earnings and revenue estimates, raised full-year EPS guidance, and posted strong gains in Alzheimer's and rare disease drugs. 
Via Benzinga
News headline image
Biogen (NASDAQ:BIIB) Reports Bullish Q2
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above... 
Via StockStory
Topics Artificial Intelligence
News headline image
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.